Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ECCO-2: Echinacea Formulation for Mild Covid-19
NCT04981314Phase 4Unknown
- Start
- Jun 2021
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Treatment with echinacea with Placebo (2 arms). Primary endpoint: Duration of Fever at 4 weeks. Status: unknown.
02
Drugs
echinacea extract
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04981314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04981314.